BTF Overview

  • Founded
  • 1999
  • Status
  • Acquired/​Merged
  • Employees
  • 24
  • Latest Deal Type
  • M&A

BTF General Information


Manufacturer and supplier of quantitative biological reference materials and standards for the life sciences sector. The company provides reference samples for analytical laboratories to use in the quality control of their testing processes.

Contact Information

Ownership Status
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Medical Supplies
Other Industries
Other Devices and Supplies
Parent Company
Primary Office
  • PO Box 599
  • North Ryde, New South Wales 1670
  • Australia
+61 (02) 0000 0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

BTF Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Merger/Acquisition 11-Sep-2007 Completed Generating Revenue
2. Accelerator/Incubator 03-Oct-2005 Completed Startup
1. Seed Round Completed Startup
To view BTF’s complete valuation and funding history, request access »

BTF Executive Team (2)

Name Title Board Seat Contact Info
Graham Vesey Ph.D Co-Founder & Chief Technology Officer
Mark Gauci Co-Founder & Chief Executive Officer
To view BTF’s complete executive team members history, request access »

BTF Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

BTF Former Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Kestrel Capital PE/Buyout Minority 000 0000 000000 0
Pittsburgh Life Sciences Greenhouse Venture Capital Minority 000 0000 000000 0
To view BTF’s complete investors history, request access »